西地那非联合硫酸镁治疗新生儿持续性肺动脉高压的临床研究被引量：21

西地那非联合硫酸镁治疗新生儿持续性肺动脉高压的临床研究

下载PDF

导出

摘要目的观察西地那非联合硫酸镁治疗新生儿持续性肺动脉高压(PPHN)的临床效果及安全性。方法将118例PPHN患儿随机分为三组。A组39例,用西地那非口服治疗。B组37例应用硫酸镁静脉滴注。C组42例应用西地那非联合硫酸镁治疗。所有患儿分别于治疗前、后监测肺动脉压力(SPAP)、动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)及体循环收缩压(SBP)的变化。计算各组治疗有效率。结果三组治疗后6～12h、24～48h及治疗结束后的SPAP、PaO2、PaCO2与治疗前相比差异有统计学意义。而西地那非联合硫酸镁组治疗后1～2hSPAP、PaO2、PaCO2与治疗前相比差异有统计学意义;与对照组比较,SPAP下降更快(P<0.05),PaO2改善更明显(P<0.05),且SBP无明显下降,治疗有效率最高。结论西地那非联合硫酸镁治疗新生儿持续性肺动脉高压效果良好,是一种简单、经济、安全的方法。 Objective To evaluate the effect of Sildenafil combined with magne-sium sulphate for the treatment of persistent pulmonary hypertension of newbor n.Methods 118 neonate patients were randomLy divided into three groups, 39 cases in group A, oral treatment with sildenafil. 37 cases in group B application of magnesium sulfate intravenous infusion. 42 cases in group C application of sildenafil combined with magnesium sulfate. Pulmonary artery pressure （SPAP）, arterial partial pressure of oxygen （PaO2）, arterial partial pressure of carbon dioxide （PaCO2） and systemic systolic blood pressure （SBP） were observed. Results After treatment, SPAP,PaO2 and PaCO2 markedly improved by the time of 6-12,24-48 h after treatmen and the end of treament.As compared with B and C groups, PaO2 value elevated while PaCO2 and SPAP level declined after treatment in group C,with a significant difference （P0.05） ,SBP had no obvious decline. Conclusion Intravenous magnesium sulphate infusion and oral sildenafil are effective in the treatment of neonatal persistent pulmonary hypertension, but the combination of the two is rapider, safer, and more effective.

作者杨爱琳牛俊红梁发强范华军高文涛韩永才

机构地区聊城市妇幼保健院

出处《当代医学》 2012年第30期11-13,共3页 Contemporary Medicine

关键词新生儿西地那非硫酸镁肺动脉高压 Sildenafil Magnesium sulphate Persistent pu1monary hypertension Reonate

分类号 R722.1 [医药卫生—儿科]

引文网络
相关文献

参考文献6

1张志钢,陈浪,傅万海.影响新生儿肺动脉高压疗效的危险因素[J].广东医学,2011,32(3):342-344. 被引量：25
2Abu-Osba YK,GaIaI O,Manasra K,et al.Treatment of sereve persistent puimonary hypenrtension of the newborn with magnesium su phate[J]. Archd is Child,1992,67(1 Suppl No):31-35.
3Tolsa JF, Cotting J,$ekarski N,et al.Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the new born [J].Arch Dis Child,1995,72(3):F184-187.
4方俊梅,包晓珍,马撄.西地那非治疗新生儿持续肺动脉高压的临床疗效观察[J].浙江实用医学,2011,16(4):278-279. 被引量：19
5Leuchte HH, Schwa, iblrre, fr M, Baumgar'cner R,A, et al . Hemodynamieresponse to sildenafil, nitrfcoxide, and f]oprost in primary pulmonary Hypertension[J]. Chest, 2004, 125(2): 580-586.
6Mikhaii GW,Prasad 8 K,Li W,et al.Clinical arid haemodynamic effects of sildenafil in pulmonary hypertension:aeute and midterm effects[J].Eur Heart 2004,25(5):431-456.

二级参考文献15

1杜军保,石云.新生儿持续肺动脉高压[J].中国新生儿科杂志,2006,21(3):181-184. 被引量：19
2金汉珍,黄德珉,官希吉.实用新生儿学.3版.北京:人民卫生出版社,2008:770-771.
3VAN MARTER L J.Persistent pulmonary hypertension of the newborn[M]∥CLOHERTY J P,STARK A R.Manual of neonatal care.Philadelphia:Lippincott-Raven,1998:363-369.
4CHRISTINA D C,SONIA H D,LINDA J,et al.Selective serotonin-reuptake inhibitors and risk of Persistent pulmonary hypertension of the newborn[J].N Engl J Med,2006,354(6):579-587.
5BARNES P J.Endothelins and pulmonary diseases[J].Appl Physiol,1994,77(3):1051.
6ENRIQUE O M Jr,ESTERLITA V T,GIRIJA N,et al.Persistent pulmonary hypertension of the newborn:Pathogenesis,Etiology,and Management[J].Pediatr Drugs,2006,8(3):179-188.
7SILVANI P,CAMPORESI A.Drug-induced pulmonary hypertension in newborns:A review[J].Curr Vasc Pharmacol,2007,5(2):129-133.
8Ghofrani H A, Pepke - Zaba J, Barbera J A, et al. Nitric oxide path -way and phosphodiesterse inhibittors in pulmonary arterial hy- pertension. J Am Coil Cardiol, 2004, 43(12):68.
9Leoche H H, Schwaiblmair M, Bamngartner R A, et al. Hemody- namie response to sildenafil, nitricoxide, and iloprost in primary pulmonary Hypertension, Chese, 2004, 125(2) :580.
10Mikhail G W, Prasad S K, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid - term effects Eur Heart J, 2004, 25(5) :431.